NDAINHALATIONSPRAY, METERED
Approved
Sep 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4
Data completeness
4/8 — Partial
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SPIRIVA RESPIMAT is a metered-dose inhalation spray containing tiotropium bromide, a long-acting muscarinic antagonist (LAMA) approved by the FDA on September 24, 2014. It is indicated for maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma. The drug works by blocking muscarinic receptors in airway smooth muscle, promoting bronchodilation and reducing airway obstruction. SPIRIVA RESPIMAT represents the modern inhaler formulation of tiotropium, offering improved ease of use compared to older dry powder delivery systems.
$0.9BPart D
4.9 years to LOEMechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Characteristics of Pts Initiating Spiriva Respimat in Asthma
Started Mar 2019
116,133 enrolled
Asthma
Specific Use-Result of Spiriva Respimat® in Asthmatics
Started Jul 2017
193 enrolled
Asthma
Specific Use-result Surveillance of Spiriva Respimat in Asthmatics
Started Jun 2015
359 enrolled
Asthma
Observational Non-Interventional Study With Spiriva Respimat in COPD Patients
Started Jun 2008
1,280 enrolled
Pulmonary Disease, Chronic Obstructive
Why This Matters for Your Career
Worked on SPIRIVA RESPIMAT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.